CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues		$ 615.4	$ 543.3	$ 1,211.6	$ 1,055.7
Operating expenses:
Salaries and benefits		181.9	155.3	360.8	307.0
Supplies		173.5	157.5	345.1	304.8
Professional and medical fees		66.7	57.4	130.3	112.9
Lease expense		20.2	22.6	40.2	45.4
Other operating expenses		38.5	32.2	75.8	63.8
Cost of revenues		480.8	425.0	952.2	833.9
General and administrative expenses		26.1	24.5	55.6	51.3
Depreciation and amortization		28.0	25.2	55.4	50.9
Transaction and integration costs		8.2	9.2	15.3	14.5
Grant funds		(0.1)	(4.9)	(1.3)	(20.0)
Loss on disposals and deconsolidations, net		1.1	1.0	1.0	0.1
Equity in earnings of unconsolidated affiliates		(2.6)	(3.0)	(5.7)	(5.6)
Litigation settlement		0.0	0.0	(32.8)	0.0
Loss on debt extinguishment		0.0	9.6	0.0	9.6
Other income, net		(2.6)	(2.8)	(5.0)	(2.8)
Total operating expenses		538.9	483.8	1,034.7	931.9
Operating income		76.5	59.5	176.9	123.8
Interest expense, net		(56.9)	(53.4)	(113.2)	(106.7)
Income before income taxes		19.6	6.1	63.7	17.1
Income tax (expense) benefit		(4.3)	2.7	(5.6)	2.5
Net income		15.3	8.8	58.1	19.6
Less: Net income attributable to non-controlling interests		(33.7)	(35.7)	(64.3)	(67.5)
Net loss attributable to Surgery Partners, Inc.		(18.4)	(26.9)	(6.2)	(47.9)
Less: Amounts attributable to participating securities		0.0	0.0	0.0	(10.3)
Net loss attributable to common stockholders		$ (18.4)	$ (26.9)	$ (6.2)	$ (58.2)
Net loss per share attributable to common stockholders
Basic (in USD per share)		$ (0.21)	$ (0.39)	$ (0.07)	$ (0.94)
Diluted (in USD per share)	[1]	$ (0.21)	$ (0.39)	$ (0.07)	$ (0.94)
Weighted average common shares outstanding
Basic (shares)		88,900	69,267	88,450	62,060
Diluted (shares)	[1]	88,900	69,267	88,450	62,060

[1] The impact of potentially dilutive securities for all periods presented was not considered because the effect would be anti-dilutive.